Learn what EU/mg, EU/mL and not-detected results mean, which laboratory details to request, and why an endotoxin claim is not proof of safety.
An endotoxin result needs a unit, a reporting limit and a clearly identified sample. “Passed” or “not detected” alone does not establish that a peptide vial is sterile or suitable for human use. The practical task is to find out what the laboratory actually measured before comparing suppliers' claims.
This guide concerns analytical reports for research materials. It does not provide a human-use acceptance limit or an injection protocol. Sources and the example supplier listing were checked October 4, 2026.
EU means endotoxin unit, a measure of endotoxin activity. It is not a bacterial cell count or a chemical-purity percentage. Endotoxins are associated with Gram-negative bacteria; their presence does not require those bacteria to remain alive. FDA's historical technical guide explains this distinction and the relationship between mass-based and volume-based results. Its 1985 regulatory limits should not be treated as current specifications. FDA technical background
Read the denominator:
Ask what “mg” means: labeled fill, gross powder or measured peptide content. The COA guide explains why those quantities can differ. Also check whether the reported result already includes dilution corrections; applying them twice creates a new error.
Consider two fictional reports, unrelated to any supplier:
| Report | Entry |
|---|---|
| A | Less than 0.10 EU/mg |
| B | Less than 0.05 EU/mL |
B's smaller number does not make it the better result. If its final reported liquid contains 0.25 mg/mL of the same defined material, dividing 0.05 EU/mL by 0.25 mg/mL gives a reporting bound of 0.20 EU/mg. If the concentration instead were 1 mg/mL, the bound would be 0.05 EU/mg.
This is unit arithmetic, not a safety assessment. Both entries are bounds, not measured values equal to those numbers. The concentration, mass basis and any prior correction must be known before making the comparison. Even comparable units do not establish that the samples, methods or sampling plans were equivalent.
A test has a finite ability to detect endotoxin. A report below its stated limit does not demonstrate absolute zero. Ask whether the laboratory is reporting a detection limit, a quantification limit or a limit-test outcome.
Dilution can reduce interference from a sample, but it also reduces the endotoxin concentration presented to the assay. Charles River's technical explanation links sensitivity selection to interference and the maximum valid dilution. A very low instrument limit is not automatically the reporting limit for the original material. Assay sensitivity and dilution
The laboratory should also establish that the product does not invalidate the test. A positive product control adds a known amount of endotoxin to assess recovery in the sample. Ask whether the control met the method's criteria and whether the method was shown suitable for this formulation. A successful control supports the assay; it is not a clinical safety study. Charles River validation FAQ
LAL is one assay family. Recombinant methods also exist: USP Chapter 86 describes recombinant Factor C and recombinant cascade reagents. A report should identify its actual method rather than use “LAL” as a catch-all for every endotoxin test. The public USP preview is a scope description, not the complete testing procedure. USP Chapter 86
Then establish whether the sample was bulk powder, a filled vial or a later preparation. FDA's March 2026 guidance addresses sampling, storage, handling and pooling; combining samples can dilute an unusually contaminated unit. A result for one material or preparation should not silently become a claim about another. Ask which lot and how many units the report represents. FDA guidance, questions 1–4
An endotoxin result is also not a sterility result or a screen for every possible pyrogen. Do not substitute one test's conclusion for another. The same FDA guidance explains that relevant acceptance limits depend on the product and its intended conditions; a number copied from another product is not a universal research-peptide threshold.
The existing Real Peptides TB-500 listing, available through our TB-500 identity guide, advertises endotoxin screening below 0.1 EU/mg. That is a seller's claim, not a batch result independently verified by Biomogging. Before comparing it with another offer, request the matching lot report, the mass basis, the tested material, the reporting limit and method-suitability information. Supplier listing
Affiliate disclosure: Biomogging may earn a commission through supplier links in the linked identity guide. We have not tested this product. An analytical claim does not establish an approved human treatment, and research labeling does not resolve that question. FDA's August 2026 warning letter illustrates why intended human use and drug approval must be assessed separately from research disclaimers.
A useful request to the laboratory is specific: “Please explain whether this result is corrected to the original material, what the denominator represents, which units were sampled, and whether the product-control and suitability checks passed.” Keep unresolved answers visible; do not convert missing documentation into either a pass or an accusation of fraud.
Powered by BTST